Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
SOC Telemed buys specialty telemedicine provider for $194M
After going public through a SPAC merger last year, SOC Telemed bought acute telemedicine provider Access Physicians for $194 million. The deal is expected to bolster the company’s specialty consults and telemedicine services for hospitals.
Shares0
Months after becoming a publicly traded company, acute telemedicine provider SOC Telemed made its largest acquisition to date. It acquired specialty telemedicine provider Access Physicians for $194 million in cash and stock last week.
Unlike consumer-facing telemedicine companies, such as Doctor on Demand, SOC Telemed primarily sells its services to hospitals and clinics. It has a platform that lets hospitals build their own telemedicine programs, and offers consults from neurologists, psychiatrists, critical care physicians and pulmonologists.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade
Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade
FDA approval of Supernus Pharmaceuticals drug Qelbree gives attention-deficit hyperactivity disorder patients another treatment option that is not classified as a Schedule II substance. It’s a different formulation of a drug that was first approved in Europe decades ago.
Shares0
Attention-deficit hyperactivity disorder (ADHD) can be addressed by several medicines already commercially available but there’s now another treatment option and it’s the first new FDA-approved drug of its type in more than a decade.
MedCity News
How to overcome AI’s healthcare headwinds
AI has already shown tremendous promise for everything from automating patient communication and non-clinical administrative tasks to reducing physician burnout. But realizing that promise more broadly requires AI developers to establish trust with their healthcare users.
Shares0
The bloom may be off the rose when it comes to the use of AI in healthcare, as multiple missteps have cast doubt on whether the technology can deliver real change for the industry. IBM’s recent decision to spin off Watson Health demonstrates just how difficult it can be to apply AI to some of healthcare’s trickiest challenges–and how easy it is to create cynicism among would-be users. AI efforts also have been tainted by biased datasets, creating tools that perpetuate inequality. Even some useful AI tools, like hospice software that helps caregivers maximize facetime with their sickest patients, have caused frustration and confusion when re